Dx Deals: Labcorp and BioReference Health Agree on $225m Sale of Some Assets
Labcorp will acquire oncology-related clinical tests services from BioReference’s parent company, OPKO Health
Keeps You Up-to-Date on Lab Business and Competitive Strategy, Market Trends and Opportunities, and M&A and Investment Activity in Today’s Diagnostic Lab Industry
Labcorp will acquire oncology-related clinical tests services from BioReference’s parent company, OPKO Health
The board was eliminated as part of a sweeping reordering of the Department of Health and Human Services
A leaked budget document for the next fiscal year suggested non-user fee funding may be up slightly compared to recent years.
The role at this point is theoretical, but our editors asked AI for help in drafting what the position might entail
While still in the early stages, Clinical Lab 2.0’s pitch for this new position fits with the need to better use lab data
However, a new memo instructs federal prosecutors to ‘avoid overreach’ when parties cooperate with authorities
CAP and AMP officials weigh in on plans to push for a legislative- or CLIA-based approach to future LDT oversight
Recent inroads into testing of water for dialysis equipment illustrates Quest’s expanded scope with deals
Marginal LDT scenarios could be where the FDA focuses on next, a lawyer notes
Options include establishing career trajectory plans and offering smooth onboarding for incoming laboratory scientists
Judge rules that the FDA has ‘no authority’ to issue its rule governing laboratory-developed tests